Comment on the safety and effectiveness of tirofiban in acute coronary syndrome

Objective: To explore the safety and effectiveness of tirofiban in treatment of acute coronary syndrome(ACS) .Methods: Eighty patients with ACS were divided into observation group and control group(40 cases each group) .The routine treatments were performed for the patients in control group，while tirofiban was administered additionally to the patients in observation group.Cardiac troponin T(cTnT) peak level in 24 hour was compared，major adverse cardiac events in 30d， rate of fall of ST segment， left ventricular ejection fraction， adverse reactions and bleeding condition were observed in two groups.Results: There was no bleeding even slight bleeding or thrombocytopenia in either case， and there was no difference of the occurrence rate of bleeding in skin and mucosa between the observation group and control group(20.0% vs.17.5%) (P0.05) .The cTnT peak level in 24 hours in observation group was obviously lower than that in control group，(1.47 0.58) g /L vs.(2.34 0.49) g /L(P0.05) .There was no difference about the occurrence rates of major adverse cardiac events in 30d in both groups(2.5% vs.12.5%) (P0.05) .The rate of fall of ST segment (80.0%) and left ventricular ejection fraction(57.8 6.7) % in observation group were significantly better than those in control group， 60.0% and (45.4 4.8 ) %，(P0.05 ) .Conclusions: For ACS patients， tirofiban based on the routine treatment can effectively decrease the incidence of myocardial cell injury， and it can improve cardiac function.There is a tendency that tirofiban can also decrease the major adverse cardiac events.Besides， its safety is better.